Cellebrite DI (NASDAQ:CLBT) Lowered to "Hold" Rating by Wall Street Zen

Key Points

• Wall Street Zen has downgraded Cellebrite DI's stock rating from "buy" to "hold," reflecting a cautious outlook on the investment potential.
• Analysts have set new target prices for Cellebrite DI, with Lake Street Capital lowering it to $22.00 and Needham & Company reducing it to $18.00, while the consensus price target remains at $22.40.
• Cellebrite DI reported earnings of $0.12 per share, surpassing estimates, with a revenue increase of 18.4% year-over-year, reaching $113.28 million for the quarter.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday.

Several other research firms also recently weighed in on CLBT. Needham & Company LLC dropped their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, August 14th. Lake Street Capital reduced their price target on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research report on Friday, August 15th. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Cellebrite DI has a consensus rating of "Buy" and an average target price of $22.40.

Cellebrite DI Stock Up 3.7%

Shares of Cellebrite DI stock traded up $0.63 during trading on Friday, hitting $17.43. The stock had a trading volume of 1,790,704 shares, compared to its average volume of 1,961,918. The stock has a 50 day simple moving average of $15.23 and a 200 day simple moving average of $16.94. The company has a market capitalization of $4.17 billion, a PE ratio of 49.41, a P/E/G ratio of 3.05 and a beta of 1.28. Cellebrite DI has a 1 year low of $13.10 and a 1 year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.01. The business had revenue of $113.28 million for the quarter, compared to the consensus estimate of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The firm's quarterly revenue was up 18.4% compared to the same quarter last year. During the same period last year, the firm posted $0.10 earnings per share. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts expect that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Squarepoint Ops LLC bought a new position in shares of Cellebrite DI in the 2nd quarter valued at approximately $675,000. Ashford Capital Management Inc. raised its stake in shares of Cellebrite DI by 2.2% in the 2nd quarter. Ashford Capital Management Inc. now owns 1,265,670 shares of the company's stock valued at $20,251,000 after acquiring an additional 27,830 shares in the last quarter. SkyView Investment Advisors LLC raised its stake in shares of Cellebrite DI by 2.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company's stock valued at $597,000 after acquiring an additional 970 shares in the last quarter. Tidal Investments LLC raised its stake in shares of Cellebrite DI by 60.9% in the 2nd quarter. Tidal Investments LLC now owns 96,157 shares of the company's stock valued at $1,539,000 after acquiring an additional 36,402 shares in the last quarter. Finally, Select Equity Group L.P. bought a new stake in Cellebrite DI during the 2nd quarter valued at approximately $5,558,000. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.